

No. 20230125-6

NOTICE

Sub: Listing of Equity Shares of Aarti Pharmalabs Limited

Trading Members of the Exchange are hereby informed that effective from **Monday, January 30, 2023**, the equity shares of Aarti Pharmalabs Limited shall be listed and admitted to dealings on the Exchange in the list of T Group of Securities. Further in terms of SEBI circular No. CIR/MRD/DP/02/2012 dated January 20, 2012; the scrip will be in Trade-for-Trade segment for 10 trading days.

Members are requested to note that the above security will be a part of special pre-open session for IPO and Other category of scrip's as per SEBI circular no. CIR/MRD/DP/01/2012 & CIR/MRD/DP/02/2012 dated January 20, 2012.

For further information on SPOS, the trading members are requested to refer to the Exchange's notice no. 20120216-29 on Enabling Special Pre-open Session for IPO's & Relisted Scrips. For any clarification on SPOS, the trading members may please contact the Helpdesk on 022-6136 3100 / 6136 3171.

Name of the Company	:	Aarti Pharmalabs Limited		
Registered Office	:	Plot No 22/C/1 & 22/C/2, 1st Phase, GIDC Vapi 396195, Valsad, Gujarat		
	:	Telephone: +91-22-6797 6666		
	:	Fax: +91-22-2565 3234		
	:	E-mail ID: co.apl@aartipharmalabs.com		
	:	Website: www.aartipharmalabs.com		
Company Secretary & Compliance Officer	:	Mr. Nikhil Natu		
	:	Tel: +91-22-67976666		
	:	Email ID: co.apl@aartipharmalabs.com		
Securities	:	9,06,26,008 Equity shares of Rs. 5/- each allotted pursuant to Scheme of Arrangement		
Distinctive numbers	:	250001 to 90876008		
Scrip Code	:	543748		
Group	:	T		
Market Lot	:	1		
Face Value & Paid up value	:	Rs. 5/- each fully paid		
Scrip ID on BOLT System	:	AARTIPHARM		
Abbreviated name on BOLT	:	AARTIPHARM		
ISIN No.	:	INE0LRU01027		
Lock-in	:	Quantity	Dist. Nos.	Lock in Upto
	:	Not Applicable		

1. The brief particulars of the Composite Scheme of Arrangement are as mentioned below:

- a) The Scheme of Arrangement of the Company was approved by the Hon'ble National Company Law Tribunal (NCLT) at Ahmedabad Bench vide its Order dated 21.09.2022.
- b) Appointed Date: 01.07.2021
- c) Effective date: 17.10.2022

d) Date of Allotment: 21.10.2022

e) Pursuant to the Scheme of Arrangement amongst Aarti Industries Ltd (Demerged Company) and Aarti Pharmalabs Ltd (Resulting Company) and their Respective Shareholders, sanctioned by the Hon'ble National Company Law Tribunal, Ahmedabad Bench; whereby upon coming into effect of the scheme and in consideration of;

For the transfer and vesting of the Pharma Division of Aarti Industries Ltd into Aarti Pharmalabs Ltd; Aarti Pharmalabs Ltd shall issue and allot Equity Shares to the shareholders of Aarti Industries Ltd in the following proportion:

“1 Fully Paid Up Equity Share of Rs. 5/- each of Aarti Pharmalabs Ltd shall be issued and allotted for every 4 Fully Paid Up Equity Shares of Rs.5/- each held in Aarti Industries Ltd”

Prior to the Scheme, the paid-up Equity Capital of Aarti Pharmalabs Ltd was Rs. 25,00,000/- consisting of 2,50,000 equity shares of face value of Rs. 10/- each and the same shall stand cancelled upon the scheme coming effect.

The issued, subscribed and paid-up equity capital of Aarti Pharmalabs Ltd post arrangement is Rs.45,31,30,040/- consisting of 9,06,26,008 equity shares of face Value of Rs. 5/- each fully paid.

2. As per Exchange Notice No 20221014-6 dated 14.10.2022, Aarti Industries Ltd had fixed Record date as 20.10.2022 for giving effect to the Scheme of Arrangement.
3. The Information Memorandum containing all the information about the company can be viewed at <https://www.bseindia.com/corporates/soa.aspx>
4. The name and address of the registrar and share transfer agent of the company is as mentioned below:

LINK INTIME INDIA PRIVATE LIMITED
C-101, 247 Park, L.B.S. Marg, Vikhroli (West),
Mumbai – 400 083, Maharashtra, India
Tel: +91 22 4918 6000
Email: ganesh.jadhav@linkintime.co.in
Website: www.linkintime.co.in

5. The shareholding pattern of the company post Scheme of Arrangement is enclosed as Annexure-I.

Rupal Khandelwal
Assistant General Manager
January 25, 2023